EFFICACY AND SAFETY OF A SINGLE TRUS-GUIDED INTRAPROSTATIC INJECTION OF NX-1207 IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA: A PHASE III EUROPEAN CLINICAL STUDY

Trial Profile

EFFICACY AND SAFETY OF A SINGLE TRUS-GUIDED INTRAPROSTATIC INJECTION OF NX-1207 IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA: A PHASE III EUROPEAN CLINICAL STUDY

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Fexapotide (Primary) ; Tamsulosin
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Registrational; Therapeutic Use
  • Acronyms ERNEST
  • Sponsors Recordati
  • Most Recent Events

    • 17 Dec 2015 Results published in Nymox media release.
    • 17 Dec 2015 Primary endpoint (Improvement in symptoms (Improvement of lower urinary tract symptoms as assessed via the International Prostate Symptom Score (IPSS) has been met, as per Nymox media release.
    • 12 Feb 2015 Status changed from recruiting to discontinued, according to a Recordati media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top